Abid H. Sayyid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abid H. Sayyid has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Anastasia Sosenko Piscitello
Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland
1 shared publicationAnn-Sofie Nilsson
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden
1 shared publication- Bennie Lemmens
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden
1 shared publication - Bruno Urién
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Giovanni Giglio
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77 Stockholm, Sweden
1 shared publication - Jiri Bartek
Genome Integrity Group, Danish Cancer Institute, Copenhagen, Denmark
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Temporal control of human DNA replication licensing by CDK4/6-RB signalling and chemical genetics
Cyclin-dependent kinases (CDKs) coordinate DNA replication and cell division, and play key roles in tissue homeostasis, genome stability and cancer development. The first step in replication is origin licensing, when minichromosome maintenance (MCM) helicases are loaded onto DNA by CDC6, CDT1 and the origin recognition complex (ORC). In yeast, origin licensing starts when CDK activity plummets in G1 phase, reinforcing the view that CDKs inhibit licensing. Here we show that, in human cells, CDK4/6 activity promotes origin licensing. By combining rapid protein degradation and time-resolved EdU-sequencing, we find that CDK4/6 activity acts epistatically to CDC6 and CDT1 in G1 phase and counteracts RB pocket proteins to promote origin licensing. Therapeutic CDK4/6 inhibitors block MCM and ORC6 loading, which we exploit to trigger mitosis with unreplicated DNA in p53-deficient cells. The CDK4/6-RB axis thus links replication licensing to proliferation, which has implications for human cell fate control and cancer therapy design.
- 12 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-15
Open AccessTemporal control of human DNA replication licensing by CDK4/6-RB signalling and chemical genetics
Cyclin-dependent kinases (CDKs) coordinate DNA replication and cell division, and play key roles in tissue homeostasis, genome stability and cancer development. The first step in replication is origin licensing, when minichromosome maintenance (MCM) helicases are loaded onto DNA by CDC6, CDT1 and the origin recognition complex (ORC). In yeast, origin licensing starts when CDK activity plummets in G1 phase, reinforcing the view that CDKs inhibit licensing. Here we show that, in human cells, CDK4/6 activity promotes origin licensing. By combining rapid protein degradation and time-resolved EdU-sequencing, we find that CDK4/6 activity acts epistatically to CDC6 and CDT1 in G1 phase and counteracts RB pocket proteins to promote origin licensing. Therapeutic CDK4/6 inhibitors block MCM and ORC6 loading, which we exploit to trigger mitosis with unreplicated DNA in p53-deficient cells. The CDK4/6-RB axis thus links replication licensing to proliferation, which has implications for human cell fate control and cancer therapy design.